Core B evaluates and follows all participants entered into the studies of the program project. It uses an established clinical and psychometric protocol at entry and annually thereafter to obtain clinical, neurological, and behavioral data to carefully characterize each participant in support of each of the 3 Projects of this Program Project Grant (PPG).
Specific Aims of Core B are: 1. Maintain the current active cohort (n=225) of participants, carefully characterized as to the presence or absence of symptomatic AD, to support longitudinal studies of the clinical, cognitive, behavioral and biomedical correlates of symptomatic Alzheimer's disease (AD) in comparison with normal aging, and to mark the transition of cognitively normal participants with preclinical AD to cognitive impairment. 2. Annually enroll and assess 35 new participants (CDR 0=23;CDR 0.5/AD =12) each year who are age e 65 to replenish the Core's cohort to maintain a sufficient sample size (n~250) to support the aims of the PPG and to supply study participants and their data (and DNA to Project 3) to individual Projects: 3. Follow all participants with annual assessments and provide diagnostic and clinical and cognitive data to all Cores and Projects, working closely with Core C: Biostatistics and Core A: Administration to coordinate data acquisition and management to integrate the Core's activities with the scientific goals of the Program Project. In addition to HASD's traditional diagnostic methods, in this application HASD participants will (in accordance with the criteria established by the Alzheimer Disease Neuroimaging Initiative-2) also be classified as significant memory concern, early and late mild cognitive impairment (MCI). 4. Support Core D: Neuropathology through our voluntary autopsy consent program. 5. Support Core E: Imaging and all Projects by referring: a. all HASD participants for MRI and PET amyloid imaging session at baseline and every 3 years thereafter;b. provide Project 1 (Indicators of transition to symptomatic AD) clinical characterizations and data from cognitive measures of all participants;c. refer to Project 2 (Sleep: potential prognostic and theranostic marker for preclinical AD) all participants for sleep and cerebrospinal fluid studies;d. Collect blood from all newly enrolled Core participants for Project 3 (Identification of genetic variants associated with the progression of AD) for their GWAS and variant characterization.

Public Health Relevance

Core B: Clinical Project Narrative As instructed by the funding opportunity announcement for this application (PAR-13-329), only the Overall component contains a project narrative. Cores and projects were instructed not to include this section.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
2P01AG003991-31A1
Application #
8739009
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (M1))
Project Start
Project End
2019-04-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
31
Fiscal Year
2014
Total Cost
$516,802
Indirect Cost
$176,497
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Adel, Tameem; Cohen, Taco; Caan, Matthan et al. (2017) 3D scattering transforms for disease classification in neuroimaging. Neuroimage Clin 14:506-517
Schindler, Suzanne E; Jasielec, Mateusz S; Weng, Hua et al. (2017) Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. Neurobiol Aging 56:25-32
Zhao, Yue; Raichle, Marcus E; Wen, Jie et al. (2017) In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. Neuroimage 148:296-304
Su, Yi; Vlassenko, Andrei G; Couture, Lars E et al. (2017) Quantitative hemodynamic PET imaging using image-derived arterial input function and a PET/MR hybrid scanner. J Cereb Blood Flow Metab 37:1435-1446
Deming, Yuetiva; Li, Zeran; Kapoor, Manav et al. (2017) Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. Acta Neuropathol 133:839-856
Day, Gregory S; Lim, Tae Sung; Hassenstab, Jason et al. (2017) Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology 88:1273-1281
Monsell, Sarah E; Mock, Charles; Fardo, David W et al. (2017) Genetic Comparison of Symptomatic and Asymptomatic Persons With Alzheimer Disease Neuropathology. Alzheimer Dis Assoc Disord 31:232-238
Mez, Jesse; Chung, Jaeyoon; Jun, Gyungah et al. (2017) Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans. Alzheimers Dement 13:119-129
Khajehnejad, Moein; Saatlou, Forough Habibollahi; Mohammadzade, Hoda (2017) Alzheimer's Disease Early Diagnosis Using Manifold-Based Semi-Supervised Learning. Brain Sci 7:
Holth, Jerrah; Patel, Tirth; Holtzman, David M (2017) Sleep in Alzheimer's Disease - Beyond Amyloid. Neurobiol Sleep Circadian Rhythms 2:4-14

Showing the most recent 10 out of 831 publications